A combination Alzheimer’s therapy targeting BACE1 and neprilysin in 5XFAD transgenic mice

BACKGROUND: Accumulating evidence indicates that partial inhibition of β-site APP-cleaving enzyme 1 (BACE1), which initiates amyloid-β (Aβ) production, mitigates Alzheimer’s disease (AD)-like pathologies and memory deficits in a battery of transgenic mouse models. However, our previous investigation...

Descripción completa

Detalles Bibliográficos
Autores principales: Devi, Latha, Ohno, Masuo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397831/
https://www.ncbi.nlm.nih.gov/pubmed/25884928
http://dx.doi.org/10.1186/s13041-015-0110-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4397831/
https://www.ncbi.nlm.nih.gov/pubmed/25884928
http://dx.doi.org/10.1186/s13041-015-0110-5

Ejemplares similares